Cramer on Kinder Morgan, AT&T, Edwards Lifesciences and More
Kinder Morgan, AT&T and Edwards Lifesciences were just some of the names in Cramer’s mailbag Thursday. But before he answered his “Mad Mail,” he presented his homework on some other names that popped up recently.
Last Friday, Adam in New York asked about two foreign stocks—Yandex and MakeMyTrip. Cramer has told homegamers to avoid Yandex, the Russian version of Google , since it went public in May and he’s sticking by that call. The company appears to be growing and recently had a strong quarter. However, he’s concerned because when the IPO lockup expires on November 21, many insiders will sell for the first time. “we want to stay on the sidelines until the selling passes,” he said.
The “Mad Money” host called Make My Trip “just to rich for me.” At 62 times next year’s earnings, its way too pricey in this volatile market, but it may be worth coming back to in a less chaotic environment.
On Monday, Bonnie in California wanted to know about Digital Realty Trust, a real estate investment trust that owns and manages technology related properties. While the idea of this stock as an emerging way to play big data, this REIT yields 4.3 percent—and that’s not enough for Cramer’s taste. If you are looking for dividends, he suggests Enterprise Products Partners , Energy Transfer Partners or MarkWest Energy Partners instead.
Bert in Colorado asked about another dividend stock, Kinder Morgan . But Cramer said he likes Kinder Morgan Energy Partners better, because it has a higher yield.
Ian wanted to know about how AT&T’s deal to purchase T-Mobile will affect both companies, as well as Sprint . Cramer likes AT&T whether the deal goes through or not. And if the deal is blocked, there may be an opportunity for T-Mobile and Sprint to team up. However, he’s not recommending Sprint right now because it is being “held hostage to the bonds.” He fears this common stock might not be worth as much as it is selling for.
Acme Packet was on Aaron’s mind. He has a long position and wanted to know where it was going. Cramer suggested taking profits because the market is just too dicey.
Alok in New York asked about Baker Hughes and Halliburton for growth, but Cramer likes Schlumberger and Ensco better.
Finally, James wanted to know how to play Edwards Lifesciences now that it has FDA approval for a heart device. Cramer thinks the heart device is being underestimated by Wall Street. “EW is going to be the ticket for a longer life with less pain for a lot of people,” he said.
Call Cramer: 1-800-743-CNBC
When this story was published, Cramer's charitable trust owned AT&T, Ensco and Schlumberger.
Questions for Cramer? email@example.com
Questions, comments, suggestions for the Mad Money website? firstname.lastname@example.org